Rivastigmine: A review of its clinical effectiveness;Rivastigmina: Una revisión de su eficacia clínica

Revista de Neurologia

Volumn 35, Issue 9, 2002, Pages 859-869

  Spiegel, R ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Activities of daily living; Alzheimer's disease; Cholinesterase inhibitors; Rivastigmine

Indexed keywords

ACETYLCHOLINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; PSYCHOTROPIC AGENT; RIVASTIGMINE;

ALZHEIMER DISEASE; BEHAVIOR; BRAIN CORTEX; CELL SURVIVAL; CHOLINERGIC NERVE CELL; CHOLINERGIC TRANSMISSION; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; DAILY LIFE ACTIVITY; DISEASE ACTIVITY; ECONOMIC ASPECT; EMOTION; FRONTOTEMPORAL DEMENTIA; HEALTH CARE COST; HIPPOCAMPUS; HUMAN; LEARNING; LIMBIC CORTEX; MEMORY; MONEY; MULTIINFARCT DEMENTIA; NERVE CELL LESION; PARKINSON DISEASE; QUALITY OF LIFE; SOCIAL ASPECT; SYMPTOM; TASK PERFORMANCE;

EID: 0036860256     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3509.2002002     Document Type: Conference Paper

References (78)

1. Terry R, Katzman R. Dementia of the Alzheimer type: Defining a disease. In Bick KL, Katzman R, Terry RD, eds. Alzheimer's Disease. New York: Raven Press; 1994. p. 51-84.
2. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer's disease and related disorders. JAMA 1997; 278: 1363-71.
3. Katzman R, Saitoh T. Advances in Alzheimer's disease. FASEB J 1991; 5: 278-86.
4. Mayeux R, Sano M. Treatment of Alzheimer's disease. N Engl J Med 1999; 341: 1670-9.
5. Cummings JL, Mendez MF. Alzheimer's disease: Cognitive and behavioral pharmacotherapy. Conn Med 1997; 61: 543-2.
6. Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA 1989; 262: 2551-6.
7. Bouchard RW, Rossor M. Typical clinical features. In Gauthier S, ed. Clinical Diagnosis and Management of Alzheimer's Disease. London: Martin Dunitz; 1996. p. 35-51.
8. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000; 54: 2261-8.
9. Tariot PN, Solomon PR, Morris JC, et al, and The Galantamine USA-10 Study Group. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000; 54: 2269-76.
10. Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer's disease: Results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10: 237-44.
11. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998; 50: 136-45.
12. Green C, Mohs RC, Schmeidler J. Functional decline in Alzheimer's disease. A longitudinal study. J Am Geriatr Soc 1993; 41: 654-61.
13. Hill LR, Klauber MR, Salmon DP. Functional status, education and the diagnosis of dementia in the Shanghai survey. Neurology 1993; 43: 138-45.
14. Barberger-Gateau P, Commenges D, Gagnon M. Instrumental activities of daily living as a screening tool for cognitive impairment and dementia in elderly community dwellers. J Am Geriatr Soc 1992; 40: 1129-34.
15. Jost BC, Grossberg GT. The evolution of psychiatric symptoms in Alzheimer's disease: A natural history study. J Am Geriatr Soc 1996; 44: 1078-81.
16. Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996; 46: 130-5.
17. Farber NB, Rubin EH, Newcomer JW, Por favor, completar hasta un máximo de 6 autores, et al. Increased neocortical neurofibrillary tangle density in subjects with Alzheimer disease and psychosis. Arch Gen Psychiatry 2000; 57: 1165-73.
18. Levy ML, Cummings JL, Fairbanks LA, et al. Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease. Am J Psychiatry 1996; 153: 1438-43.
19. Skelton WP, Skelton NK. Alzheimer's disease. Recognizing and treating a frustrating condition. Postgrad Med 1991; 90: 33-4, 37-41.
20. Geula C, Mesulam MM. Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease. In Bick KL, Katzman R, Terry RD, eds. Alzheimer's Disease. New York: Raven Press; 1994. p. 263-91.
21. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR. Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981; 10: 122-6.
22. Tekin S, Mega MS, Masterman DM, et al. Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease. Ann Neurol 2001; 49: 355-61.
23. Lyketsos CG, Steinberg M, Tschanz JT, et al. Mental and behavioral disturbances in dementia: Findings from the cache county study on memory in aging. Am J Psychiatry 2000; 157: 708-14.
24. Rösler M, Retz W, Retz-Junginger P, Dennler HJ. Effects of two-year treatment with cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behav Neurol 2000; 11: 211-6.
25. Guan ZZ, Zhang X, Ravid R, Nordberg A. Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease. J Neurochem 2000; 74: 237-43.
26. Flynn DD, Ferrari-DiLeo G, Mash DC, Levey AI. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J Neurochem 1995; 64: 1888-91.
27. Perry EK, Perry RH, Blessed G, Tomlinson BE. Changes in brain cholinesterases in senile dementia of the Alzheimer type. Neuropathol Appl Neurobiol 1978; 4: 273-7.
28. Mesulam M, Geula C. Butyryleholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann Neurol 1994; 36: 722-7.
29. Wright CI, Geula C, Mesulam MM. Neurological cholinesterases in the normal brain and in Alzheimer's disease: Relationship to plaques, tangles, and patterns of selective vulnerability. Ann Neurol 1993; 34: 373-84.
30. Giacobini E, Holmstedt B. Cholinesterase content of certain regions of the spinal cord as judged by histochemical and cartesian diver techniques. Acta Physiol Scand 1958; 42; 12-27.
31. Giacobini E. Cholinesterase inhibitors stabilize Alzheimer's disease. Ann N Y Acad Sci 2000; 920: 321-7.
32. Giacobini E. From molecular structure to Alzheimer therapy. Jpn J Pharmacol 1997; 74: 225-41.
33. Darvesh S, Grantham DL, Hopkins DA. Distribution of butyrylcholinesterase in human amygdala and hippocampal formation. J Comp Neurol 1998; 393: 374-90.
34. Costa JF, Anand R, Cutler NR, et al. Correlation between cognitive effects and level of acetylcholinesterase inhibition in a trial of rivastigmine in Alzheimer's patients. Proc Am Psych Assoc 1999 [abstract NR: 561].
35. Nordberg A, Darreh-Shori T, Svenson A, Guan Z. AChE and BuChE activities in CSF of mild AD patients following 12 months of rivastigmine treatment. J Neurol Sci 2001; 187: P0144.
36. Nordberg A, Almkvist O, Darreh-Shori T, Spiegel R. Improved cognition and plasma ChE inhibition in AD patients receiving rivastigmine for one year: Differential effects across time. J Neurol Sci 2001a; 187: P0143.
37. Nordberg A, Almkvist O, Nilsson A, Wall A, Langstrom B. Improved cortical glucose metabolism in AD patients treated with rivastigmine for one year. J Neurol Sci 2001b; 187: P0409.
38. Guillozet AL, Smiley JF, Mash DC, Mesulam MM. Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol 1997; 42: 909-18.
39. Brodaty H. Caregivers and behavioral disturbances: Effects and interventions. Intern Psychogeriatrics 1996; 8 (Suppl 3): 455-8.
40. Gauthier S, Gelinas I, Gauthier L. Functional changes in Alzheimer's disease. Alz Insights 1996; 2: 3-5.
41. Reisberg B, Ferris SH, de León MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982; 139: 1136-9.
42. Whitehouse PJ, Orgogozo JM, Becker R. Quality of life assessment in dementia drug development. Alzheimer Dis Assoc Discord 1997; 11 (Suppl 3): 56-60.
43. Heyman A, Peterson B, Fillenbaum G, et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part XIV: Demographic and clinical predictions of survival in patients with Alzheimer's disease. Neurology 1996; 46: 656-60.
44. Gauthier L, Gauthier S. Assessment of functional changes in Alzheimer's disease. Neuroepidemiology 1990; 9: 183-8.
45. Weintraub S, Baratz R, Mesulam MM. Daily living activities in the assessment of dementia. In Corkin S, et al, eds. Alzheimer's Disease: A Report of Progress, aging. New York: Raven Press; 1982. p. 189-92.
46. Kaufer DI, Cummings JL, Christine D, et al. Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: The Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc 1998; 46: 210-15.
47. Dura JR, Stukenberg KW, Kiecolt-Glaser JK. Anxiety and depressive disorders in adult children caring for demented parents. Psychol Aging 1991; 6: 467-73.
48. Wimo A, Ljunggren G, Winblad B, et al. Costs of dementia and dementia care: A review. Int J Geriatr Psychiatry 1997; 12: 841-56.
49. Ostbye T, Crosse E. Net economic costs of dementia in Canada. Can Med Assoc J 1994; 151: 1457-64.
50. Hux MJ, O'Brien BJ, Iskedjian M, et al. Relation between severity of Alzheimer's disease and costs of caring. CMAJ 1998; 159: 457-65.
51. Cummings JL. Theories behind existing scales for rating behavior in dementia. Intern Psychogeriatr 1996; 8: 293-300.
52. O'Donnell BF, Drachman DA, Barnes HJ, et al. Incontinence and troublesome behaviors predict institutionalization in dementia. J Geriatr Psychiatry Neurol 1992; 5: 45-52.
53. Steele C, Rovner B, Chase GA, Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychol 1990; 147: 1049-51.
54. Alzheimer's Association. Who Cares? Families Caring for Persons with Alzheimer's Disease. Alzheimer's Association Report; 1999.
55. EMEA. The European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products (CPMP). Note for Guidance on Medicinal Products in the Treatment of Alzheimer's Disease. September 1997, CPMP/EWP/553/95.
56. Mohr E, Feldman H, Gauthier S. Canadian guidelines for the development of antidementia therapies: A conceptual summary. Can J Neurol Sci 1995; 22: 62-71.
57. Teri LL, Logsdon RG. Methodologic issues regarding outcome measures for clinical drug trials of psychiatric complications in dementia. J Geriatr Psych Neurol 1995; 8: S8-S17.
58. Enz A, Amstutz R, Boddeke H, et al. Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease. In Cuello AC, ed. Prog Brain Res 98. Elsevier Science Publishers; 1993. p. 431-8.
59. Corey-Bloom JF, Anand R, Veach J. A randomized trail evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylchol/nesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998; 1: 55-65.
60. Rösler M, Anand R, Cicin-Sian A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. Br Med J 1999; 318: 633-40.
61. Potkin SG, Anand R, Hartman R, Veach J, Grossberg G. Impact of Alzheimer's disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe disease. Int J Neuropsychopharmacol. [In press].
62. Cummings J, Anand R, Koumaras B, Hartman R. Rivastigmine provides behavioral benefits to Alzheimer's disease patients residing in a nursing home: Findings from a 26-week trial [abstract]. Neurology 2000; 54: A468.
63. th Annual Meeting of the ANA, 2001.
64. Bullock R, Moulias R, Steinwachs KC, Cicin-Sain AG, Spiegel R. Effects of rivastigmine on behavioural symptoms in nursing home patients with Alzheimer's disease: a European, open-label, multi-centre study. Poster presented at Istanbul Conference 'Pathways from Science to Effective Patient Management in Dementia', 23-25 March 2001.
65. Messina J, Koumaras B, Hartman R. Treatment with rivastigmine reduces the need for psychotropic medications in patients with Alzheimer's disease residing in long-term care facilities. Poster presented at Crete 2000 'Maximising the ABC of Dementia'. Crete, 9-11 March 2000.
66. McKeith I, del Ser T, Spano PF, et al. Efficacy of rivastigmine in dementia with Lewy bodies: A randomised double-blind, placebo-controlled international study. Lancet 2000; 356: 2031-6.
67. Weiser M, Davidson M, Hartman R, et al. A randomised, open-label study on the safety and tolerability of the co-administration of Exelon (rivastigmine) with Risperidal (risperidone) in dementia patients with behavioural disturbances. Poster presented at Crete 2000 'Maximising the ABC of Dementia'. Crete, 9-11 March 2000.
68. Geizer M, Ancill RJ. Combination of risperidone and donepezil in Lewy body dementia. Can J Psychiatr 1998; 43: 421-2.
69. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA 1994; 271: 985-91.
70. Doraiswamy M, Anand R, Hartman R, et al. Cognitive effect of rivastigmine, a new generation cholinesterase inhibitor in moderately severe to advanced Alzheimer's disease. Poster presented at 13th AAGP 2000. Miami, Florida, USA.
71. Farlow M, Anand R, Messina J, Hartman R, Veach J. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur J Neurol 2000; 44: 236-41.
72. Kramer-Ginsberg E, Mohs RC, Aryan M, et al. Clinical predictors of course for Alzheimer patients in a longitudinal study: A preliminary report. Psychopharmacol Bull 1988; 24: 458-62.
73. Anand R, Messina J, Hartman R, Danyluk J. Long-Term Efficacy of Rivastigmine in Patients with Moderately Severe to Severe Alzheimer's Disease AAAG Poster Presentation. 2000a.
74. Potkin SG, Messina J, Graham S. Safety of rivastigmine in Alzheimer's disease: Pooled results from Phase III studies. Poster presented at World Alzheimer Congress 2000-Pivotal Research 'Alzheimer's Disease: Translating Neurochemical Insights into Clinical Benefits'. Washington, 8 July 2000.
75. Grossberg G, et al. Lack of drug-drug interactions with rivastigmine for AD. Int J Geriatr Psychiatry 2000; 15: 242-7.
76. Anand R, Gharabawi G. Clinical development of Exelon™ (ENA-713): The ADENA programme. J Drug Dev Clin Pract 1996; 8: 9-14.
77. Polinsky R. Clinical pharmacology of rivastigmine: A new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther 1998; 20: 634-47.
78. Anand R, Messina J, Hartman R. Dose-response effect of rivastigmine in the treatment of Alzheimer's disease. Int J Geriatr Psychopharmacol 2000b; 2: 68-72.